>
GURUFOCUS.COM > STOCK LIST > Healthcare > Biotechnology > PTC Therapeutics Inc (NAS:PTCT) > Definitions > Asset Turnover
Switch to:

PTC Therapeutics Asset Turnover

: 0.08 (As of Mar. 2022)
View and export this data going back to 2013. Start your Free Trial

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. PTC Therapeutics's Revenue for the three months ended in Mar. 2022 was $148.7 Mil. PTC Therapeutics's Total Assets for the quarter that ended in Mar. 2022 was $1,868.8 Mil. Therefore, PTC Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 was 0.08.

Asset Turnover is linked to ROE % through Du Pont Formula. PTC Therapeutics's annualized ROE % for the quarter that ended in Mar. 2022 was 1,137.28%. It is also linked to ROA % through Du Pont Formula. PTC Therapeutics's annualized ROA % for the quarter that ended in Mar. 2022 was -27.12%.


PTC Therapeutics Asset Turnover Historical Data

The historical data trend for PTC Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Asset Turnover
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.35 0.22 0.20 0.26

PTC Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Asset Turnover Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.07 0.08 0.08

PTC Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

PTC Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2021 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2021 )/( (Total Assets (A: Dec. 2020 )+Total Assets (A: Dec. 2021 ))/ count )
=538.593/( (2208.278+1938.056)/ 2 )
=538.593/2073.167
=0.26

PTC Therapeutics's Asset Turnover for the quarter that ended in Mar. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2022 )/( (Total Assets (Q: Dec. 2021 )+Total Assets (Q: Mar. 2022 ))/ count )
=148.735/( (1938.056+1799.591)/ 2 )
=148.735/1868.8235
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


PTC Therapeutics  (NAS:PTCT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

PTC Therapeutics's annulized ROE % for the quarter that ended in Mar. 2022 is

ROE %**(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=-506.904/-44.5715
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-506.904 / 594.94)*(594.94 / 1868.8235)*(1868.8235/ -44.5715)
=Net Margin %*Asset Turnover*Equity Multiplier
=-85.2 %*0.3184*-41.9287
=ROA %*Equity Multiplier
=-27.12 %*-41.9287
=1,137.28 %

Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

PTC Therapeutics's annulized ROA % for the quarter that ended in Mar. 2022 is

ROA %(Q: Mar. 2022 )
=Net Income/Total Assets
=-506.904/1868.8235
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-506.904 / 594.94)*(594.94 / 1868.8235)
=Net Margin %*Asset Turnover
=-85.2 %*0.3184
=-27.12 %

Note: The Net Income data used here is four times the quarterly (Mar. 2022) net income data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


PTC Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


PTC Therapeutics Business Description

PTC Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
Southwell David P director C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421
Jacobson Allan Steven director PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Peltz Stuart Walter director, officer: Chief Executive Officer PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Utter Christine Marie officer: SVP, Finance & CAO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Boulding Mark Elliott officer: Exec. VP and CLO C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Hill Emily Luisa officer: Chief Financial Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Svoronos Dawn director C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105
Pauwels Eric officer: Chief Business Officer 550 HILLS DRIVE BEDMINSTER NJ 07921
Klein Matthew B. officer: Chief Development Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Schmertzler Michael director 1300 VALLEY ROAD NEW CANAAN CT 06840
Souza Marcio officer: Chief Operating Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Almstead Neil Gregory officer: Chief Technical Ops Officer C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080
Reeve Emma director C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232
Zeldis Jerome B director 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258

PTC Therapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)